Premier Alternatives

Aro Biotherapeutics

Philadelphia, PA · Founded 2018 · Privately Held (backing)

Developer of a protein drug platform designed to unlock the potential of genetic medicines. Aro Biotherapeutics is based in Philadelphia, PA and was founded in 2018. It was valued at $182 million at its later-stage round in Nov 2023, the last priced event on record. It has raised $132 million across 4 recorded rounds; the latest was a $24 million early-stage round in Dec 2022.

PMV mark · valuation
$181.5M
Oct 2026
Priced at
its later-stage round
Nov 2023
Total raised
$131.8M
Last round
Early Stage VC
Dec 2022

Aro Biotherapeutics key facts

as of Oct 2026
  • Developer of a protein drug platform designed to unlock the potential of genetic medicines.
  • Aro Biotherapeutics is valued at approximately $181.5M as of Oct 2026, set at its later-stage round, Nov 2023; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $131.8M across 4 recorded rounds; the latest was Early Stage VC ($24.0M) in Dec 2022.
  • Notable investors include Johnson & Johnson Innovation - JLABS, Johnson & Johnson JJDC, Ridgeback Capital, Avego Management, BVF Partners — 10 tracked in total.
  • Aro Biotherapeutics has filed 7 Form Ds with the SEC since 2019, most recently Dec 2022 ($24.0M sold to 12 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$181.5M

Valued at $181.5M at its later-stage round, Nov 2023. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Aro Biotherapeutics with a free account
  • ·Watch Aro Biotherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Aro Biotherapeutics funding rounds

4 rounds
Dec 2022Early Stage VC$24.0MSEC filing▮
Dec 2020Later Stage VC$90.3MSEC filing▮
Dec 2019Early Stage VC$5.0MSEC filing▮
Mar 2019Seed Round$3.5MSEC filing▮
Full funding history →

Aro Biotherapeutics valuation

Aro Biotherapeutics was valued at $182 million at its later-stage round in Nov 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Aro Biotherapeutics raised?

Aro Biotherapeutics has raised $132 million across 4 recorded rounds since 2019. The largest was a $90.3 million later-stage round in Dec 2020; the most recent was a $24 million early-stage round in Dec 2022.

Aro Biotherapeutics has filed 7 Form Ds with the SEC since 2019, most recently in Dec 2022 ($24 million sold to 12 investors).

Aro Biotherapeutics investors

10 investors are on record for Aro Biotherapeutics, including Johnson & Johnson Innovation - JLABS, Johnson & Johnson JJDC, Ridgeback Capital and Avego Management. The early-stage round in Dec 2022 drew 12 investors.

About Aro Biotherapeutics

Developer of a protein drug platform designed to unlock the potential of genetic medicines. The company's drugs are small, non-antibody protein scaffolds that can be expressed as multi-specifics with therapeutic mechanisms of action for non-small cell lung cancer, enabling physicians to achieve efficacy and safety profiles for patients with cancer and other serious diseases.

Sector
Healthcare
HQ
Philadelphia, PA, United States
Founded
2018
Employees
49
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.